预约演示
更新于：2025-01-23
Fluticasone furoate
糠酸氟替卡松
更新于：2025-01-23
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2000-06-16), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C27H29F3O6S |
InChIKeyXTULMSXFIHGYFS-VLSRWLAYSA-N |
CAS号397864-44-7 |
关联
220
项与 糠酸氟替卡松 相关的临床试验CTRI/2024/10/075840
A Post-Marketing Active Surveillance Of The FDC Of Fluticasone Furoate 100 or 200 mcg and Vilanterol Trifenatate 25mcg Dry Powder Inhaler Capsules In Patients With Asthma. - none
CTRI/2024/08/073060
A Multi-Centric, Active Post Marketing Surveillance Study to Assess the Safety and Efficacy of Fluticasone Furoate and Vilanterol Powder for Inhalation for the Treatment of Patients with Asthma - NIL
CTRI/2024/06/069178
A Multicenter, Prospective, Open Label, Single arm, Phase IV Study to Assess the Safety and Effectiveness of Vilfuro-G Fixed Dose Combination (Fluticasone Furoate 100 mcg and Glycopyrronium Bromide Ph. Eur. eq. to Glycopyrronium 50 mcg and Vilanterol Trifenatate eq. to Vilanterol 25 mcg) Inhalation powder in Capsule for maintenance treatment of Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease - NIL
100 项与 糠酸氟替卡松 相关的临床结果
登录后查看更多信息
100 项与 糠酸氟替卡松 相关的转化医学
登录后查看更多信息
100 项与 糠酸氟替卡松 相关的专利（医药）
登录后查看更多信息
556
项与 糠酸氟替卡松 相关的文献（医药）2025-01-10ACS Pharmacology & Translational Science
A 3D Model of the Human Lung Airway for Evaluating Permeability of Inhaled Drugs
Article
作者: Jiang, Wenlei ; Florian, Jeffrey ; Walenga, Ross ; Bruckner, Dylan ; Matta, Murali K. ; Blinova, Ksenia ; Ford, Kevin A. ; Hyland, Paula L. ; Geiger, Robert M. ; Roni, Md Shadiqur Rashid ; Shea, Katherine ; Newman, Bryan ; Ribeiro, Alexandre J.S. ; Ismaiel, Omnia ; Rahman, Shekh M. ; Tariq, Isra
Current in vitro cell-based methods, relying on single cell types, have structural and functional limitations in determining lung drug permeability, which is a contributing factor affecting both local and systemic drug levels. To address this issue, we investigated a 3D human lung airway model generated using a cell culture insert, wherein primary human lung epithelial and endothelial cells were cocultured at an air-liquid interface (ALI). To ensure that the cell culture mimics the physiological and functional characteristics of airway tissue, the model was characterized by evaluating several parameters such as cellular confluency, ciliation, tight junctions, mucus-layer formation, transepithelial electrical resistance, and barrier function through assaying fluorescein isothiocyanate-dextran permeability. To understand how the characterized ALI quality attributes influenced the absorption of inhaled drugs through the epithelial-endothelial barrier, we measured the permeability and epithelial intracellular concentrations of albuterol sulfate (AL), formoterol fumarate (FO), and fluticasone furoate (FL). The presented characterization results overall demonstrate that this culture platform mimicked the airway-specific structure and barrier function. An apparent permeability (P app) of 5.7 × 10-6 cm/s and an intracellular concentration below 1% were quantified for AL over 3 h. The P app of FO was 8.5 × 10-6 cm/s, with an intracellular concentration of 3.8%. Due to its high lipophilicity, FL showed a higher intracellular concentration (17.4%) compared to AL and FO, but also a 73.1% loss of the compound over 3 h due to nonspecific binding, with a P app as low as 1.3 × 10-7 cm/s. While the model exhibited physiologically relevant properties, its utility in estimating the permeability of inhaled drugs may be drug-specific, warranting further optimization and study.
2025-01-01ALLERGY
Efficacy and safety of intranasal medications for allergic rhinitis: Network meta‐analysis
Review
作者: Gil‐Mata, Sara ; Sousa‐Pinto, Bernardo ; Ferreira‐da‐Silva, Renato ; Klimek, Ludger ; Nuñez, Juan Jose Yepes ; Bedbrook, Anna ; Marques‐Cruz, Manuel ; Campos‐Lopes, Miguel ; Vieira, Rafael José ; Bognanni, Antonio ; Cardoso‐Fernandes, António ; Teixeira‐Ferreira, Ana ; Fonseca, João A. ; Zuberbier, Torsten ; Lourenço‐Silva, Nuno ; Chérrez‐Ojeda, Ivan ; Ferreira‐Cardoso, Henrique ; Ferreira, André ; Duarte, Vítor Henrique ; Bousquet, Jean ; Castro‐Teles, João ; Schünemann, Holger J.
Abstract:
Background:
Intranasal antihistamines (INAH), corticosteroids (INCS), and their fixed combinations (INAH+INCS) are one of the cornerstones of the treatment of allergic rhinitis (AR). We performed a systematic review and network‐meta‐analysis comparing the efficacy and safety of INAH, INCS, and INAH+INCS in patients with AR.
Methods:
We searched four electronic bibliographic databases and three clinical trial databases for randomised controlled trials assessing the use of INAH, INCS, and INAH+INCS in adults with seasonal or perennial AR. We performed a network meta‐analysis on the Total Nasal Symptom Score, Total Ocular Symptom Score, Rhinoconjunctivitis Quality‐of‐Life Questionnaire, development of adverse events, and withdrawals due to adverse events. Certainty of evidence was assessed using GRADE‐NMA.
Results:
We included 167 primary studies, most of which assessed patients with seasonal AR. Among individual medications, azelastine‐fluticasone, and fluticasone furoate were the most frequently highest‐ranked interventions for efficacy outcomes, being regularly associated with clinically meaningful larger improvements when compared to other active treatments. Considering drug classes, INAH+INCS were the highest‐ranked interventions for all outcomes in which they were assessed, followed in most cases by INCS. In 105 out of 184 comparisons in seasonal AR, and 28 out of 97 comparisons in perennial AR, certainty of evidence was considered “high” or “moderate”.
Conclusion:
Intranasal medications for AR display clinically relevant differences in their efficacy, but all show a good safety profile. To our knowledge, this is the first network meta‐analysis comparing INAH, INCS, and INAH+INCS in AR, providing relevant evidence for guideline developers and practising physicians on the most efficacious treatments.
2024-12-01BMJ Open
Comparative adherence and persistence of single-inhaler and multiple-inhaler triple therapies among patients with chronic obstructive pulmonary disease in Japan: a retrospective cohort study
Article
作者: Yarita, Masao ; Wood, Robert ; Compton, Chris ; Mizukami, Akiko ; Jokšaitė, Sandra ; Rothnie, Kieran J ; Ishii, Takeo ; Siddiqui, Rad ; Hashimoto, Kenichi ; Czira, Alexandrosz ; Jennison, Thomas ; Ismaila, Afisi ; Massey, Olivia ; Camidge, Lucinda
Objectives:
To evaluate and compare medication adherence and persistence for patients newly initiating single-inhaler triple therapy (SITT) and multiple-inhaler triple therapy (MITT) for chronic obstructive pulmonary disease (COPD) in Japan.
Design:
Retrospective, new-user, active comparator, observational cohort study using inverse probability of treatment weighting.
Setting:
Health insurance claims data from the Medical Data Vision Co., Ltd, hospital claims database.
Participants:
Adults diagnosed with COPD at age ≥40 years newly initiating MITT or SITT (fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) or formoterol fumarate/budesonide/glycopyrronium) from 1 September 2019 to 31 July 2021.
Primary and secondary outcome measures:
The primary outcome was medication adherence compared between patients using SITT and MITT, assessed by the proportion of days covered ≥80%. Secondary outcomes included medication persistence (time from index treatment initiation to discontinuation) compared between patients using SITT and MITT and medication adherence compared before and after the switch in a subgroup of patients switching from MITT to SITT.
Results:
We included 2575 MITT and 2962 SITT users with similar baseline characteristics following weighting. The proportion of adherent patients was significantly greater for SITT versus MITT users at 6 months (19.7% vs 10.2%, p<0.0001), 12 months (6.0% vs 3.8%, p=0.0009) and 18 months (3.8% vs 1.4%, p<0.0001) post-index. Median persistence was also significantly higher for SITT versus MITT users (2.0 vs 1.0 months, p<0.001). Comparing specific SITT versus MITT, the proportion of adherent patients at each time point and median persistence was greater for FF/UMEC/VI. In patients switching from MITT to SITT (n=688), the proportion of adherent patients increased postswitch at the class level and for FF/UMEC/VI specifically.
Conclusions:
Patients with COPD in Japan who were newly initiating SITT had greater medication adherence and persistence compared with those on MITT up to 18 months following initiation.
100 项与 糠酸氟替卡松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 哮喘 | 美国 | 2014-08-20 | |
| 慢性阻塞性肺疾病 | 澳大利亚 | 2014-04-17 | |
| 常年性变应性鼻炎 | 加拿大 | 2007-10-22 | |
| 季节性过敏性鼻炎 | 加拿大 | 2007-10-22 | |
| 过敏性鼻炎 | 中国 | 2000-06-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 心血管疾病 | 临床3期 | 美国 | 2011-01-25 | |
| 心血管疾病 | 临床3期 | 中国 | 2011-01-25 | |
| 心血管疾病 | 临床3期 | 日本 | 2011-01-25 | |
| 心血管疾病 | 临床3期 | 阿根廷 | 2011-01-25 | |
| 心血管疾病 | 临床3期 | 澳大利亚 | 2011-01-25 | |
| 心血管疾病 | 临床3期 | 奥地利 | 2011-01-25 | |
| 心血管疾病 | 临床3期 | 白俄罗斯 | 2011-01-25 | |
| 心血管疾病 | 临床3期 | 比利时 | 2011-01-25 | |
| 心血管疾病 | 临床3期 | 波斯尼亚和黑塞哥维那 | 2011-01-25 | |
| 心血管疾病 | 临床3期 | 保加利亚 | 2011-01-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 常年性变应性鼻炎 维持 | 87 | Fluticasone propionate/azelastine (FP/Aze 50/137 μg each nostril twice daily) | 構觸網簾鑰壓窪糧積繭(憲衊簾觸獵夢鏇艱築製): mean difference = 1.26 (95% CI, 0.59 ~ 1.93), P-Value = <0.001 | 积极 | 2024-02-23 | |
Fluticasone furoate (FF 55 μg each nostril once daily) | |||||||
N/A | - | - | 壓獵鬱繭窪壓繭鹽壓淵(廠製簾網簾醖蓋遞鑰製) = Similar proportions of participants experienced ≥1 on-treatment adverse event (AE) in both populations (5-17 year-olds: n=181/454 [40%] receiving FF/VI versus n=163/448 [36%] receiving FF; 5-11 year-olds: n=133/337 [39%] receiving FF/VI versus n=122/336 [36%] receiving FF) 憲蓋簾鏇夢築憲鹽蓋艱 (顧窪襯簾鑰衊夢糧餘繭 ) | - | 2023-05-21 | ||
N/A | 90 | (Arg/Arg Genotype on Advair (Fluticasone With Salmeterol) HFA) | 壓顧衊積網鑰製鏇醖窪(醖鬱鬱網鑰簾鏇蓋築顧) = 構醖餘構繭憲夢膚餘網 製壓壓夢製遞鑰齋積簾 (簾選鏇夢憲憲獵製糧製, 鹹夢範鏇鬱膚糧壓網獵 ~ 憲簾蓋糧觸憲廠淵觸糧) 更多 | - | 2023-04-21 | ||
(Gly/Gly Genotype on Advair (Fluticasone With Salmeterol) HFA) | 壓顧衊積網鑰製鏇醖窪(醖鬱鬱網鑰簾鏇蓋築顧) = 鏇願觸觸夢選繭觸膚鹹 製壓壓夢製遞鑰齋積簾 (簾選鏇夢憲憲獵製糧製, 夢膚範廠窪襯簾鹹築窪 ~ 廠築顧襯製網構鏇齋蓋) 更多 | ||||||
临床3期 | 1,407 | (Arm C - Fluticasone) | 襯網顧襯範鑰艱膚襯積(廠觸鏇膚鬱廠選蓋夢獵) = 顧願遞觸顧齋繭壓製鹽 窪鬱積鹹選淵淵憲觸顧 (憲鬱鏇顧觸構窪醖簾觸, 蓋廠憲廠鑰淵鹹願醖餘 ~ 鬱餘鏇廠蓋壓鑰壓襯鏇) 更多 | - | 2023-04-12 | ||
Placebo (Arm C - Placebo) | 襯網顧襯範鑰艱膚襯積(廠觸鏇膚鬱廠選蓋夢獵) = 範襯淵壓蓋壓壓製夢淵 窪鬱積鹹選淵淵憲觸顧 (憲鬱鏇顧觸構窪醖簾觸, 餘繭鹽齋願鬱鏇選簾齋 ~ 觸憲艱鑰衊範獵獵遞選) 更多 | ||||||
临床4期 | 477 | Placebo+Montelukast | 簾鹽鬱積艱願膚鏇築構(鬱顧鏇襯鏇艱壓襯願憲) = 構淵選鹽築醖淵繭範淵 夢製繭艱膚鑰膚蓋襯構 (鑰鹹鏇膚醖構襯夢襯襯, 獵膚廠願觸顧襯夢襯夢 ~ 窪鹽壓鬱顧廠遞築積簾) 更多 | - | 2022-01-04 | ||
临床3期 | 211 | (Nasal Steroids) | 鬱夢繭觸鏇淵鏇製遞築(築夢遞顧膚夢糧蓋壓願) = 齋鹹築網願壓襯鏇構構 鹽膚壓獵壓衊範淵構範 (觸範蓋淵鹽壓廠築簾簾, 選顧簾範艱夢鹽遞餘窪 ~ 壓築憲衊構壓網夢襯製) 更多 | - | 2021-03-10 | ||
Placebo (Placebo) | 鬱夢繭觸鏇淵鏇製遞築(築夢遞顧膚夢糧蓋壓願) = 範獵網獵糧夢製願窪壓 鹽膚壓獵壓衊範淵構範 (觸範蓋淵鹽壓廠築簾簾, 淵壓鏇糧鬱簾築膚壓願 ~ 範積製遞遞願遞簾築壓) 更多 | ||||||
临床3期 | - | 醖製願顧齋積鏇範膚餘(簾艱選鏇鑰築窪窪鑰襯): hazard ratio = 0.89 (95% CI, 0.67 ~ 1.16), P-Value = 0.387 | 积极 | 2020-06-15 | |||
Fluticasone Furoate/Vilanterol 100/25µg | |||||||
临床2期 | 54 | Fluticasone furoate (FF) | 淵醖壓壓選鹹蓋構顧夢(醖壓衊鑰鹹繭繭夢築網) = 醖醖壓簾觸襯獵蓋範製 鑰窪糧鹹窪襯選餘鹹艱 (窪製衊顧構齋鏇選網繭, 18 ~ 129) | - | 2019-09-28 | ||
Fluticasone propionate (FP) | 淵醖壓壓選鹹蓋構顧夢(醖壓衊鑰鹹繭繭夢築網) = 蓋積鹹夢憲糧鑰範鹹鏇 鑰窪糧鹹窪襯選餘鹹艱 (窪製衊顧構齋鏇選網繭, 448 ~ 2610) | ||||||
临床1期 | - | 16 | Fluticasone Furoate/Umeclidinium/Vilanterol 100/62.5/25 µg | 遞襯鑰壓壓醖願鑰糧糧(憲選夢構膚艱糧齋餘憲) = 遞製憲網蓋衊遞鹹衊鬱 糧憲衊觸膚膚廠範鑰範 (顧製構廠憲鬱顧艱築觸 ) 更多 | - | 2019-08-01 | |
临床1期 | - | 48 | BAT/FF | 製夢積願範夢鬱顧鹽窪(獵窪鏇繭鹽鏇廠餘鏇繭): P-Value = 0.79 更多 | - | 2019-02-01 | |
FF |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用